Archive · 24 Jul 2026
Trump's Pharma Tariffs: Winners and Losers
President Trump wants to put high tariffs on generic medicines imported to the US.
This could hurt Indian pharma companies that sell a lot of medicines in the US.
Aurobindo Pharma is the most at risk because it gets a lot of its money from the US.
Torrent Pharmaceuticals is the least at risk because it doesn't rely as much on the US market.
Sun Pharmaceutical has a mix of generic and branded drugs, so it's in a different position.
Moving medicine production to the US would take a long time and might make it harder for people to get the medicines they need.
US President Donald Trump proposed tariffs of up to 200% on imported generic medicines.
Indian pharmaceutical companies with significant US business are concerned about the impact.
Aurobindo Pharma has the highest exposure to the US generics market, making it the most vulnerable.
Torrent Pharmaceuticals has the lowest exposure to the US market, reducing its risk.
Sun Pharmaceutical has a diversified portfolio with both generic and branded drugs in the US.
- Who
- US President Donald Trump, Indian pharmaceutical companies (Aurobindo Pharma, Torrent Pharmaceuticals, Sun Pharmaceutical)
- What
- Proposal to impose tariffs of up to 200% on imported generic medicines
- When
- Not specified
- Where
- United States
- Why
- To potentially strengthen domestic pharmaceutical production
High Exposure Companies
Low Exposure Companies
Aurobindo Pharma
High Exposure Companies
Highest exposure to US generics market, most vulnerable to tariffs
Low Exposure Companies
Not applicable
Torrent Pharmaceuticals
High Exposure Companies
Not applicable
Low Exposure Companies
Lowest exposure to US generics market, least vulnerable to tariffs
Sun Pharmaceutical
High Exposure Companies
Diversified portfolio with branded and generic drugs, less vulnerable
Low Exposure Companies
Not applicable
- Proposed Tariff Rate
- Up to 200%
- Indian Pharma Market Share in US
- More than 45%
- Aurobindo Pharma US Revenue Share
- Largest share among covered companies
- Torrent Pharmaceuticals US Revenue Share
- Lowest among covered companies
- Sun Pharmaceutical US Portfolio
- Mix of generic and branded products
- Implementation Challenges
- Relocating manufacturing takes years, could worsen medicine shortages